Maxion Therapeutics (”Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, announced today that it has raised $72 million (£58 million) in a Series A financing. Maxion is developing a proprietary pipeline of KnotBody® molecules with “first-in-class" and “best-in-class" potential. Maxion’s lead KnotBody® programme, MAX001, is currently in preclinical development to target a broad spectrum of inflammatory diseases such as atopic dermatitis and inflammatory bowel disease. Source: Maxion press release 17/3/2025